Which country is Jisandai/Bingtongsha produced? Which pharmaceutical company manufactures

Epclusa is a direct antiviral drug (DAA) developed and produced by the American pharmaceutical company Gilead Sciences. It is mainly used to treat chronic hepatitis C (HCV) infection in adults and children. Gilead Sciences, headquartered in Foster City, California, is a world-renowned biopharmaceutical company that focuses on the research and development of antiviral drugs, especially in the fields of hepatitis C, HIV, and COVID-19.

The active ingredients of Epclusa include Sofosbuvir and Velpatasvir, which when combined can cover all six hepatitis C genotypes (GT1-6), making it the first pan-genotypic hepatitis C treatment regimen. Sofosbuvir is an NS5B polymerase inhibitor, while velpatasvir is an NS5A inhibitor. Their synergistic effect can effectively block viral replication and improve the cure rate. Gilead Sciences' drugs are usually manufactured at multiple production bases around the world. Epclusa's main production bases include the United States, Canada, Ireland and other countries. The specific production locations may change due to different supply chains and market demand.

In addition, in order to improve accessibility for hepatitis C patients around the world, Gilead Sciences has cooperated with multiple generic drug manufacturers to authorize the production of generic versions of Gilead III in countries such as India, Bangladesh, and Egypt. These generic drugs are basically the same as the original drugs in terms of active ingredients, dosage and efficacy, but are cheaper and are mainly supplied to patients in low- and middle-income countries. Many pharmaceutical companies in India, such as Mylan and Natco, have obtained authorization from Gilead to produce third-generation generic drugs of Gilead, allowing more hepatitis C patients to obtain effective treatment at a lower cost.

Gisanda is a globally recognized treatment option for hepatitis C. It has been approved by the World Health Organization (WHO) and the U.S. Food and Drug Administration (FDA), and has been included in the hepatitis C treatment guidelines of many countries. Therefore, when choosing drugs, patients need to ensure that they purchase original drugs or compliant generic drugs from regular channels to avoid quality issues affecting the treatment effect.

Reference: https://www.epclusa.com/